Igc pharma presents genetic toxicology safety data on api in igc-ad1, at the 2025 genetic toxicology association meeting

Potomac, md / access newswire / may 12, 2025 / igc pharma, inc. (nyse american:igc) ("igc" or the "company") today announced that it presented its latest scientific poster, titled "genetic toxicity evaluation of melatonin in the bacterial reverse mutation assay," at the 2025 genetic toxicology association annual meeting, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("api") in igc-ad1, the company's investigational drug for alzheimer's disease. part of the fda's battery of safety requirements is to show that apis are safe for human consumption, including that they do not alter or mutate genes.
IGC Ratings Summary
IGC Quant Ranking